Core Insights - North China Pharmaceutical reported a revenue of approximately 5.275 billion yuan for the first half of 2025, representing a year-on-year increase of 0.84% [2] - The net profit attributable to shareholders of the listed company was approximately 123 million yuan, showing a significant year-on-year increase of 71.56% [2] - Basic earnings per share reached 0.072 yuan, which is an increase of 71.43% compared to the previous year [2]

Financial Performance - The company's operating revenue for the first half of the year is 5,275,037,790.20, showing a slight increase from 5,231,120,589.63 in the same period last year [1] - Total profit increased to 214,036,244.45 from 150,008,425.67 year-on-year [1] - Net profit attributable to shareholders increased to 123,497,402.89 from 71,984,395.89 year-on-year [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose to 119,946,433.69 from 54,349,775.94 year-on-year [1] - Basic earnings per share and diluted earnings per share increased due to improved budget management and cost control measures [1] Cash Flow and Assets - The net cash flow from operating activities decreased to 491,498,056.91 from 883,182,799.92 year-on-year [2] - Net assets attributable to shareholders at the end of the reporting period are 5,467,083,266.95, slightly up from 5,389,402,984.11 at the end of the previous year [1] - Total assets increased to 21,752,942,040.92 from 21,471,458,316.43 year-on-year [1] Non-recurring Gains and Losses - The increase in net profit attributable to shareholders after deducting non-recurring gains and losses is primarily due to a significant reduction in non-recurring gains and losses compared to the same period last year [2]

Core Viewpoint - The report highlights the financial performance and operational strategies of North China Pharmaceutical Co., Ltd. for the first half of 2025, showcasing growth in revenue and profit despite challenges in the pharmaceutical industry [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 reached approximately 5.28 billion RMB, a slight increase of 0.84% compared to the same period last year [2][10]. - Total profit amounted to approximately 214 million RMB, reflecting a significant increase of 42.68% year-on-year [2][10]. - Net profit attributable to shareholders was approximately 123.5 million RMB, up 71.56% from the previous year [2][10]. - The basic earnings per share increased to 0.072 RMB, a rise of 71.43% compared to the same period last year [2][10]. Business Overview - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various pharmaceutical products, including antibiotics, biological drugs, vitamins, and health consumer products [3][4]. - North China Pharmaceutical has established a comprehensive product chain from raw materials to finished dosage forms, maintaining a leading position in the antibiotic sector [4][5]. Market Position and Industry Context - The pharmaceutical manufacturing industry in China is currently facing pressures such as declining profits and overall sluggish growth, with a reported 1.2% decrease in revenue for the first half of 2025 [3][6]. - Despite these challenges, the long-term outlook for the industry remains positive due to factors such as economic growth, an improving healthcare system, and increasing health awareness among the population [3][6]. Operational Strategies - The company has implemented measures to enhance efficiency and reduce costs, including centralized procurement and lean management practices [5][6]. - North China Pharmaceutical is focusing on expanding its international market presence, particularly in high-end markets like Japan, and has achieved export revenues of approximately 1.1 billion RMB in the first half of 2025 [5][6]. Research and Development - The company has increased its R&D investment to approximately 456 million RMB, representing an R&D intensity of 8.64% [6][10]. - Several new products are in the pipeline, including generic drugs and biological products, with ongoing efforts to meet consistency evaluation standards for generic drugs [6][10]. Risk Management and Quality Control - The company emphasizes strict quality control throughout the production process, ensuring compliance with national standards and maintaining a 100% pass rate in national quality inspections [7][8]. - Risk management practices have been strengthened, including regular internal audits and environmental inspections [6][8].

| 华北制药股份有限公司2025 年半年度报告摘要 | | | | | --- | --- | --- | --- | | 公司代码：600812 公司简称：华北制药 | | | | | 华北制药股份有限公司 | | | | | 年半年度报告摘要 | 华北制药股份有限公司2025 | | | | 第一节 | 重要提示 | | | | 展规划，投资者应当到 网站仔细阅读半年度报告全文。 | www.sse.com.cn | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 报告期内，公司无半年度利润分配预案或资本公积金转增股本预案。 | | | | | 第二节 | 公司基本情况 | | | | 公司股票简况 | | | | | 股票种类 | 股票上市交易所 | 股票简称 | 股票代码 变更前股 | | 票简称 | | | | | A股 | 上海证券交易所 华北制药 | | 600812 无 | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | 姓名 | 肖志广 | 杨静 | | | 电话 | 0311-87173756 | 0311-8 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-045 华北制药股份有限公司 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年半年度报告》和《2025 年 半年度报告摘要》。 表决结果：同意 9 票； 反对 0 票； 弃权 0 票。 上述议案已经董事会审计委员会审议通过，并同意提交公司董事会审 议。 （二）审议通过《关于冀中能源集团财务有限责任公司的风险持续评 估报告》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 二次会议于 2025 年 8 月 1 日向全体董事、监事及公司高级管理人员以电子 邮件形式发出会议通知，以现场表决方式于 2025 年 8 月 13 日在公司会议 室召开。本次会议应出席董事 9 名，实际出席董事 9 名，会议由董事长王 立鑫先生主持。会议的召集、召开和表决程序符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司 ...

Core Viewpoint - The report evaluates the financial risk and operational status of Jizhong Energy Group Financial Co., Ltd., highlighting its compliance, risk management, and financial performance as of June 30, 2025 [1][13]. Financial Company Overview - Jizhong Energy Group Financial Co., Ltd. was established in 1998 and has undergone several capital increases, with a current registered capital of 55 billion RMB [1][3]. - The company has three main shareholders: Jizhong Energy Group, Jizhong Energy Co., Ltd., and North China Pharmaceutical Group, with respective ownership stakes of 45%, 35%, and 20% [2][3]. Compliance and Risk Control - The financial company operates under a robust governance structure, including a board of directors and various departments dedicated to risk control and internal auditing [4][12]. - It adheres to strict internal control measures and regulatory requirements, ensuring compliance with national financial regulations [5][12]. Operational Performance - As of June 30, 2025, the financial company reported total assets of 202.90 billion RMB and total liabilities of 142.28 billion RMB, with a net profit of 1.31 billion RMB for the first half of 2025 [13]. - The company maintains a capital adequacy ratio of 30.54% and a liquidity ratio of 65.78%, indicating strong financial health [13]. Risk Management Practices - The financial company has established comprehensive risk management policies, including credit risk assessment and monitoring systems for its lending activities [8][9]. - It has implemented various management measures to prevent internal operational risks and ensure the safety of client funds [6][7]. Shareholder Transactions - As of June 30, 2025, the shareholders' deposits and loans with the financial company were reported, with North China Pharmaceutical Group having a deposit balance of approximately 39.37 million RMB [14][16]. - The company has facilitated significant transactions, including commercial bill discounts totaling 4 billion RMB for North China Pharmaceutical Group [15]. Risk Assessment Conclusion - The financial company is deemed to operate within legal frameworks, with no significant violations of financial regulations reported [17]. - It has maintained a high level of loan loss provisions, ensuring that all member units are able to meet their repayment obligations without delays [17].

Group 1 - The company reported a revenue of 5.275 billion yuan for the first half of 2025, representing a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders of the listed company was 123 million yuan, showing a significant year-on-year increase of 71.56% [1] - The basic earnings per share were 0.072 yuan [1]

华北制药股份有限公司 关于冀中能源集团财务有限责任公司的 风险持续评估报告 根据《上海证券交易所上市公司自律监管指引第5号— —交易与关联交易》的要求，华北制药股份有限公司(以下简 称"华北制药"或"公司")通过查验冀中能源集团财务有限 责任公司（以下简称"财务公司"）的《金融许可证》、《企 业法人营业执照》等证件资料，并审阅包括资产负债表、利 润表、现金流量表等在内的财务公司的定期财务报告，对其 经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、财务公司基本情况 财务公司前身为华北制药集团财务有限责任公司，是经 中国人民银行（银复[1993]245号）批准成立，1998年8月18 日 取 得 《 企 业 法 人 营 业 执 照 》 （ 统 一 社 会 信 用 代 码 91130000104337206A）。2009年，依据冀国资字[2009]84号 文件要求，冀中能源集团有限责任公司（以下简称"冀中能 源集团"）对华北制药集团有限责任公司实施了战略重组， 并收购其持有华北制药集团财务有限责任公司的股份成为 华北制药集团财务有限责任公司股东。2009年，经中国银行 业监督管理委员会河北监管局（银监冀 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-045 华北制药股份有限公司 第十一届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 二次会议于 2025 年 8 月 1 日向全体董事、监事及公司高级管理人员以电子 邮件形式发出会议通知，以现场表决方式于 2025 年 8 月 13 日在公司会议 室召开。本次会议应出席董事 9 名，实际出席董事 9 名，会议由董事长王 立鑫先生主持。会议的召集、召开和表决程序符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《2025年半年度报告全文及摘要》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年半年度报告》和《2025 年 半年度报告摘要》。 表决结果：同意 9 票； 反 ...

Financial Performance - Basic earnings per share for the first half of 2025 increased by 71.43% to CNY 0.072 compared to CNY 0.042 in the same period last year[22]. - Diluted earnings per share also rose by 71.43% to CNY 0.072 from CNY 0.042 year-on-year[22]. - The net profit attributable to shareholders of the listed company increased significantly, driven by enhanced budget control and lean management practices[22]. - The weighted average return on net assets improved by 0.93 percentage points to 2.266% from 1.340% in the previous year[22]. - The basic earnings per share after deducting non-recurring gains and losses increased by 118.75% to CNY 0.070 from CNY 0.032 year-on-year[22]. - The weighted average return on net assets after deducting non-recurring gains and losses increased by 1.18 percentage points to 2.199% from 1.020%[22]. - The total profit increased, reflecting the company's efforts in cost reduction and efficiency improvement measures[22]. - Total profit for the same period reached RMB 214 million, reflecting a significant growth of 42.68% compared to the previous year[25]. - Net profit attributable to shareholders was RMB 123.5 million, up 71.56% year-on-year[25]. - The net profit after deducting non-recurring gains and losses was RMB 119.9 million, representing a 120.69% increase from the previous year[25]. Revenue and Cash Flow - The company's operating revenue for the first half of 2025 was RMB 5.28 billion, a year-on-year increase of 0.84%[25]. - The company's net cash flow from operating activities decreased by 44.35% to RMB 491.5 million[25]. - Cash inflow from investment activities was ¥60,008,200.00 in the first half of 2025, compared to ¥1,256,500.00 in the same period of 2024, showing a substantial increase[114]. - Cash outflow from investment activities totaled ¥235,625,353.31 in the first half of 2025, down from ¥328,681,651.53 in the first half of 2024, indicating a decrease of about 28.3%[114]. - The net cash flow from financing activities was -¥514,056,160.34 in the first half of 2025, compared to a positive cash flow of ¥356,142,997.81 in the same period of 2024[114]. Assets and Liabilities - As of the end of the reporting period, the net assets attributable to shareholders were RMB 5.47 billion, an increase of 1.44% from the previous year[25]. - Total assets at the end of the reporting period amounted to RMB 21.75 billion, up 1.31% from the previous year[25]. - Total liabilities amounted to ¥13,702,975,739.11, compared to ¥13,257,882,326.66 in the previous year, indicating a growth of 3.35%[105]. - Total current assets as of June 30, 2025, amounted to ¥8,564,390,541.75, an increase from ¥8,259,279,869.84 at the end of the previous year[100]. - Current liabilities rose to ¥12,108,718,070.56 from ¥10,961,529,998.42, indicating an increase of approximately 10.5%[101]. Research and Development - R&D investment for the first half of the year was CNY 456 million, with an R&D intensity of 8.64%[35]. - The company launched multiple generic drug projects in fields such as anti-infection and cardiovascular diseases, with several products approved for clinical trials[35]. - Research and development expenses increased to ¥169,073,874.09, up 5.9% from ¥160,550,724.60 in the previous year[108]. Market and Industry Context - The pharmaceutical manufacturing industry is facing pressures of overall weakness and profit decline, with a projected revenue decrease of 1.2% for the first half of 2025[31]. - The company is focusing on high-value and high-growth projects, particularly in the biopharmaceutical sector, while consolidating its chemical drug business[28]. - The company achieved export revenue of CNY 1.10 billion in the first half of the year, focusing on high-end markets in Japan and completing orders in Thailand and the Philippines[34]. Corporate Governance and Compliance - There were no major risks that materially affected the company's operations during the reporting period[8]. - The company has maintained compliance with all relevant laws and regulations, ensuring no non-operational use of funds by shareholders or related parties[70]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[66]. Community and Environmental Initiatives - The company is implementing a rural revitalization plan, deploying 6 team members to support poverty alleviation efforts in specific villages[60]. - The company is focusing on industry assistance by planning deep processing of crops to increase income and create local employment opportunities[60]. - The company has completed various community service projects, including repairing damaged infrastructure and enhancing public services in the villages[60]. Shareholder Information - Total number of common shareholders as of the end of the reporting period is 83,985[86]. - The largest shareholder, Jizhong Energy Co., Ltd., holds 413,080,473 shares, representing 24.08% of total shares[88]. - The total number of shares held by the top ten shareholders accounts for a significant portion of the company's equity, with the top three alone holding over 55%[88]. Financial Instruments and Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[133]. - The company will implement new accounting standards starting January 1, 2024, with no significant impact on the financial statements expected[132]. - Financial assets will be classified based on the business model and cash flow characteristics, including those measured at amortized cost and fair value[152].